254 related articles for article (PubMed ID: 19793344)
1. Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.
Jacobsen R; Møldrup C; Christrup L
Pain Med; 2009 Nov; 10(8):1442-51. PubMed ID: 19793344
[TBL] [Abstract][Full Text] [Related]
2. Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners.
Jacobsen R; Møldrup C; Christrup L
J Opioid Manag; 2010; 6(4):259-68. PubMed ID: 20862906
[TBL] [Abstract][Full Text] [Related]
3. Clinical rationale for administering fentanyl to cancer pain patients: two Delphi surveys of pain management experts in Denmark.
Jacobsen R; Møldrup C; Christrup L
J Opioid Manag; 2008; 4(6):383-91. PubMed ID: 19192766
[TBL] [Abstract][Full Text] [Related]
4. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
7. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
8. Oral transmucosal fentanyl citrate for cancer breakthrough pain: a review.
Gordon DB
Oncol Nurs Forum; 2006 Nov; 33(2):257-64. PubMed ID: 16518441
[TBL] [Abstract][Full Text] [Related]
9. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
Borgbjerg FM; Rosenberg J
Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
[TBL] [Abstract][Full Text] [Related]
10. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries.
Mahar PJ; Rana JA; Kennedy CS; Christopher NC
Pediatr Emerg Care; 2007 Aug; 23(8):544-8. PubMed ID: 17726413
[TBL] [Abstract][Full Text] [Related]
11. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
12. [Breakthrough pain frequency in cancer patients and the efficiency of oral transmucosal fentanyl citrate].
Bilen A; Ali A; Baturay F; Altan A
Agri; 2010 Jul; 22(3):103-8. PubMed ID: 20865581
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of oral transmucosal fentanyl citrate for prehospital pain control on the battlefield.
Wedmore IS; Kotwal RS; McManus JG; Pennardt A; Talbot TS; Fowler M; McGhee L
J Trauma Acute Care Surg; 2012 Dec; 73(6 Suppl 5):S490-5. PubMed ID: 23192075
[TBL] [Abstract][Full Text] [Related]
14. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
[TBL] [Abstract][Full Text] [Related]
15. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
Landy SH
Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
[TBL] [Abstract][Full Text] [Related]
16. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
17. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines.
Aronoff GM; Brennan MJ; Pritchard DD; Ginsberg B
Pain Med; 2005; 6(4):305-14. PubMed ID: 16083461
[TBL] [Abstract][Full Text] [Related]
18. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ).
Taylor DR; Webster LR; Chun SY; Reinking J; Stegman M; Shoemaker S; Fortner B
Pain Med; 2007 Apr; 8(3):281-8. PubMed ID: 17371416
[TBL] [Abstract][Full Text] [Related]
19. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain.
Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H
Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339
[TBL] [Abstract][Full Text] [Related]
20. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
Tawfik MO; Bryuzgin V; Kourteva G;
Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
